News

From the Center for Lyme Action: In good news, we are excited to announce that the House Appropriations Committee has approved the following increases for Lyme, alpha-gal, and other tick-borne diseases: +$2M for CDC Vector-Borne Diseases (now 65.3M) +$10M NIH Lyme and tickborne... Read More »

The Bay Area Lyme Foundation has announced the launch of Bay Area Lyme Ventures, a new impact fund designed to fast-track promising diagnostics and therapeutics for tick-borne diseases. Lyme Ventures aims to bridge the gap between academic breakthroughs and real-world solutions... Read More »

From the Center for Lyme Action: With five active tick-borne disease bills in the House of Representatives, we need all hands on deck to make sure these critical measures move forward. Your voice matters, and by meeting virtually with your U.S. Representative’s office, you can... Read More »

A new joint initiative has launched to keep Illinois residents and visitors safe from tick-borne illnesses. The Illinois Lyme Association (ILA), in collaboration with the Illinois Department of Public Health (IDPH) and the Illinois Department of Natural Resources (IDNR), has... Read More »

Children’s National Hospital in Washington, DC is conducting a groundbreaking study on how Lyme disease during pregnancy may affect child development. Led by Dr. Sarah Mulkey, the research team is looking for 40 participants to join this study and help us learn about the impacts... Read More »

A major new initiative is aiming to change the way we understand women’s health—starting with the uterus. The Fairbairn Menstruation Science Fund, launched by the MIT Health and Life Sciences Collaborative (MIT HEALS), is backed by a $10 million gift from philanthropists Emily... Read More »

This summer has seen a lot of US news reports about the rise of alpha-gal syndrome (AGS), a tick-induced allergy to red meat and other mammal-related products. AGS is a delayed hypersensitivity reaction to galactose-α-1,3-galactose, a carbohydrate found in mammalian meat,... Read More »

A recent study published in Emerging Infectious Diseases reveals that non-White Lyme disease patients in the U.S. are more likely to be diagnosed at later stages of the illness compared to White patients. Researchers analyzed Medicaid and Medicare claims data from 2016 to 2021... Read More »

60 Degrees Pharmaceuticals is launching a new clinical trial at Mount Sinai Health System to test Arakoda (tafenoquine) for chronic babesiosis. This tick-borne illness is caused by Babesia parasites that infect red blood cells. The trial will focus on patients who have... Read More »